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The effect of apolipoprotein 
E polymorphism on serum 
metabolome – a population-based 
10-year follow-up study
Juho-Pekka Karjalainen1, Nina Mononen1, Nina Hutri-Kähönen2, Miikael Lehtimäki1, 
Markus Juonala3, Mika Ala-Korpela4,5,6,7,8,9, Mika Kähönen10, Olli Raitakari11 & 
Terho Lehtimäki1
Apolipoprotein E (apoE) is the key regulator of plasma lipids, mediating altered functionalities in 
lipoprotein metabolism – affecting the risk of coronary artery (CAD) and Alzheimer’s diseases, as well 
as longevity. Searching pathways influenced by apoE prior to adverse manifestations, we utilized a 
metabolome dataset of 228 nuclear-magnetic-resonance-measured serum parameters with a 10-year 
follow-up from the population-based Young Finns Study cohort of 2,234 apoE-genotyped (rs7412, 
rs429358) adults, aged 24–39 at baseline. At the end of our follow-up, by limiting FDR-corrected 
p < 0.05, regression analyses revealed 180/228 apoE-polymorphism-related associations with the 
studied metabolites, in all subjects – without indications of apoE x sex interactions. Across all measured 
apoE- and apoB-containing lipoproteins, ε4 allele had consistently atherogenic and ε2 protective effect 
on particle concentrations of free/esterified cholesterol, triglycerides, phospholipids and total lipids. 
As novel findings, ε4 associated with glycoprotein acetyls, LDL-diameter and isoleucine – all reported 
biomarkers of CAD-risk, inflammation, diabetes and total mortality. ApoE-subgroup differences 
persisted through our 10-year follow-up, although some variation of individual metabolite levels was 
noticed. In conclusion, apoE polymorphism associate with a complex metabolic change, including 
aberrations in multiple novel biomarkers related to elevated cardiometabolic and all-cause mortality 
risk, extending our understanding about the role of apoE in health and disease.
Coronary artery disease (CAD) along with carotid artery disease and consequent strokes are the leading causes 
of death worldwide – according to the latest statistics ca. 15 million people died of these cardiovascular diseases 
(CVD) in 20161. In addition, as populations around the world are rapidly ageing2, the importance of paying atten-
tion to the causes of atherosclerotic plaque formation and its clinical consequences are also increasing. It has been 
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shown that genetic components affect the atherosclerosis and CAD risk3,4. However, the genetic or epigenetic 
mechanisms targeted for improved prevention and treatment by personalized medicine are not yet known well 
enough.
Apolipoprotein E (apoE) is a glycoprotein consisting of 299 amino acids, and it functions as the key regulator 
of plasma lipid levels. Two single-nucleotide polymorphisms (SNPs, rs429358 and rs7412) at locus 19q13.31 
determine three common allelic variants of the apoE gene: ε2, ε3 and ε4. Respectively, these alleles code three 
protein isoforms: E2, E3 and E4. Of the six apoE genotypes, ε2/2, ε3/2, ε3/3, ε4/2, ε4/3 and ε4/4, the homozygote 
ε3/3 is the most prevalent, so called reference (or parent) genotype, and the E3 isoform of the protein is associated 
with normal (i.e., average) plasma lipid levels. Compared with E3, E2 and E4 isoforms have been discovered to 
have altered functionalities in promoting clearance of triglyceride (TG) rich lipoproteins from plasma5,6. The 
reported prevalence of different alleles within human population is by average: ε2/7%, ε3/78% and ε4/14%6. The 
associations of ε4 with elevated serum total cholesterol and LDL (low-density lipoprotein) cholesterol (LDL-C) 
values have been recognized for a long time7 and the allele ε4 has been linked to the risk of atherosclerosis8 and 
CAD, whereas ε2 has been shown to e.g., reduce carotid artery intima-media thickness and coronary artery calci-
fication9,10. Nevertheless, there are also further presented hypotheses for the effects of apoE polymorphism on the 
development and severity of CAD and other diseases5,6,11,12. For example, apoE also regulates lipid transport and 
cholesterol homeostasis in the brain and the ε4 allele has been linked to Alzheimer’s disease6,11 – another common 
killer among an ageing population. Finnish population has higher than average incidence of atherosclerosis and 
the nationwide prevalence of ε4 has been reported to be about 20%7,13.
While the causality of high serum total cholesterol and LDL-C with CAD is a generally recognized feature, 
LDL-C itself may not be sensitive or specific enough for predicting atherogenesis14. For example, LDL-TG has 
been recommended as a more targeted parameter15, whereas a recent systematic review suggests several novel 
CAD risk markers found by state-of-art lipidomics and metabolomics methods14. On the other hand, the signif-
icance of apoE polymorphism on the susceptibility and development of CAD is also debated – it has been inves-
tigated in several different studies, both epidemiologically and clinically, often with controversial results16–19. In 
conclusion, further research is needed on clarifying the metabolic pathways and mechanisms of the pathogenesis 
of CAD – as well as on the role of genetic control, including apoE.
Nevertheless, an autopsy study of middle-aged Finnish men has indicated that apoE polymorphisms associate 
with the area of total atherosclerotic lesions in age- and tissue-dependent manner8. On the other hand, studies 
with relatively young Finnish subjects have not found evidence of apoE polymorphism being an independent 
genetic determinant of early atherosclerosis signs - carotid artery compliance (CAC), carotid artery intima media 
thickness (IMT) and brachial artery flow-mediated dilation (FMD)20,21. However, polymorphisms of apoE, as well 
as its promoter have been recognized to associate with standard lipid and lipoprotein profile changes of young 
and middle-aged Finns20,22,23.
Worldwide, despite numerous apoE-related association studies for standard serum lipid profiles24, 
much-needed information is clearly lacking at more detailed and thorough serum metabolome level. The serum 
metabolite profile can be defined significantly more comprehensively and accurately with high-throughput serum 
nuclear magnetic resonance (NMR) spectroscopy25, which has been used in the cohort profiling of our present 
study. With more thorough quantification combined with our systematically followed, large cohort we aim to 
clarify apoE functionalities linked to metabolic pathways of atherogenesis and regulation of longevity – thus 
extending our current understanding about the role of apoE in health and disease.
Materials and Methods
Study population and data sources. The Cardiovascular Risk in Young Finns Study (YFS) is a Finnish 
longitudinal general population study on the evolution of cardiovascular risk factors from childhood to adult-
hood26. The study began in 1980, when 3,596 children and adolescents aged 3–18 years were randomly selected 
from five university hospital catchment areas in Finland. In 2001, 2,288 participants aged 24–39 years attended 
the 21-year follow-up. 2,200 participated in the 27-year follow-up in 2007, and 2,063 contributed to the 31-year 
follow-up in 2011. Of these subjects, we included those for whom the apoE genotype data and at least 80% of 
the NMR-measured metabolic parameters were available. Therefore, 2,234 participants (2001), 2,148 partici-
pants (2007) and 1,918 participants (2011) contributed to the cross-sectional association analyses of apoE gen-
otype and serum metabolic profile. In the longitudinal analyses for comparing the metabolic level differences 
between two follow-up measurements, we included the subjects who attended both the follow-ups in ques-
tion – 1,751 participants (2001–2007), 1,734 participants (2007–2011) and 1,647 participants (2001–2011). In 
two-way repeated-measurement analyses of variances, we included 1,471 subjects who attended all the three 
consecutive follow-ups (2001, 2007, 2011). The YFS was approved by the 1st ethical committee of the Hospital 
District of Southwest Finland and by local ethical committees (1st Ethical Committee of the Hospital District of 
Southwest Finland, Regional Ethics Committee of the Expert Responsibility area of Tampere University Hospital, 
Helsinki University Hospital Ethical Committee of Medicine, The Research Ethics Committee of the Northern 
Savo Hospital District and Ethics Committee of the Northern Ostrobothnia Hospital District). The study protocol 
of each study phase corresponded to the proposal by the World Health Organization. All present subjects gave 
written informed consent and the study was conducted in accordance with the Helsinki declaration. At prior 
follow-ups of YFS, informed consent of every participant under the age of 18 was obtained from a parent and/or 
legal guardian.
Clinical and biochemical measurements and their use in statistical standardization. To elim-
inate effects of the most probable error sources, a comprehensive set of clinical background information was 
analysed as confounding candidates. The effect of BMI (measured weight [kg]/measured height squared [m²]) 
was considered by including it in the final regression models as a covariate. Based on questionnaires, daily 
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smoking (yes/no), hormonal birth control of women (yes/no), cholesterol lowering medication (yes/no) and 
socio-economic status based on occupation (manual/lower non-manual/upper non-manual) were all tested as 
covariates to associate with several different metabolic levels, but to have negligible or zero effect on the apoE 
β-values. The distributions of alcohol consumption (daily portions based on a questionnaire, one portion equal-
ling 12 g of pure alcohol) and physical activity index (graded 5–15, the higher the value the more physically active, 
evaluation method described elsewhere27) were well comparable in every analysed apoE subgroup and therefore 
not confounding. Also, there were only a few pregnant women and persons with diagnosed diabetes (evaluated 
with questionnaires) and their distributions did not differ in the analysed subgroups. Parameters describing the 
cardiovascular status, such as systolic blood pressure (defined as an average of three consecutive measurements 
with random-zero mercury sphygmomanometer), hypertension (based on a questionnaire for medically diag-
nosed hypertension, yes/no) and high-sensitivity CRP (hs-CRP, measured with an automatic analyser Olympus 
AU400) might well reflect variations of metabolic measures, i.e., could be considered more as consequent rather 
than confounding factors. Nevertheless, differences in these measures between the subgroups were also found to 
be minor – a significant majority of the study population being basically healthy. Based on the described back-
ground analyses and to avoid unnecessary selection error, additional exclusions were not made in the final anal-
yses. The effect of possible information bias may well be neglected in our results, when comparing the subgroups 
to each other – bias (if any) being presumably distributed comparably.
ApoE genotyping. ApoE alleles (ε2, ε3, ε4) were determined based on SNPs rs7412 and rs429358 haplo-
types. Genomic DNA was extracted from peripheral blood leukocytes by using QIAamp DNA Blood Minikit and 
automated biorobot M48 extraction (Qiagen, Hilden, Germany). Genotyping was performed by using Taqman 
SNP Genotyping Assays (C__904973_10, C_3084793_20) and ABI Prism 7900 HT Sequence Detection System 
(Applied Biosystems, Foster City, CA, USA). As a quality control, water controls, random duplicates and known 
control samples were run in parallel with unknown DNA samples.
Metabolic profiling. High-throughput NMR spectroscopy was used for the absolute quantification of serum 
metabolites. The metabolomics set includes 228 quantified metabolic parameters (detailed description given in 
a Supplementary Table S1) and covers multiple metabolic pathways, including lipoprotein lipids and subclasses, 
fatty acids and fatty acid compositions, as well as amino acids and glycolysis precursors. All molecular measures 
are quantified in a single experimental setup, constituting both established and novel metabolic risk factors. This 
NMR-based metabolite profiling has previously been used in various epidemiological and genetic studies28 and 
has been reviewed recently25. Details of the experimentation have been described elsewhere25,29. In addition, we 
used standard lipid panels (described in30) for comparing/verifying our metabolomics lipid results.
Statistical methods. All statistical analyses were conducted with R program version >3.1.2 (https://
www.r-project.org/) using PC. To facilitate comparisons across all metabolites, association magnitudes (β-values) 
are reported in scaled standard deviation (SD) fractions (units) of normalized, ln-transformed metabolite con-
centrations. In sex-stratified cross-sectional analyses, separate sex-specific scaling was applied to NMR measures.
Cross-sectional and longitudinal associations of apoE genotype and serum metabolic profile were analysed 
using linear multivariable regression models, with each metabolic measure (in the longitudinal analyses the dif-
ference of the corresponding metabolic measures) as the outcome and apoE genotype as the main explanatory 
value. All the regression models were adjusted for age and BMI, in the longitudinal analyses used models were 
adjusted also for BMI-change. The effect of sex was analysed in both ways with models stratified by sex, as well 
as models with sex as a covariate. Interaction of apoE and BMI (apoE × BMI, apoE × BMI-change) was tested to 
have negligible or zero effect on the apoE β-values and was therefore excluded from the final models. Prior to test-
ing the interaction effects of BMI, measures of BMI and BMI-change were mean-centred. Similarly, interaction 
of apoE and sex (apoE × sex) was excluded from the final models for not showing an effect within any metabolite 
(tested p > 0.05). ApoE genotype was included in the model as a categorical variable. First, the overall effect of 
apoE genotype on the linear fit was F-tested with implementing the Benjamini-Hochberg procedure31 in false 
discovery rate (FDR) correction and setting the limit at p < 0.05. After that, apoE genotypes were post-hoc com-
pared with each other with t-tests (implementing FDR correction), the values of which were inherited from the 
linear regression function (lm) in R. 95% confidence intervals were also calculated, allowing a better comparison 
of the apoE groups.
In two-way repeated-measures analyses of variances, isolated missing measures of random individuals were 
mean value replaced. As described above, the analysis was performed with ln-transformed and scaled (normal-
ized) data. The independent variables (time and apoE genotype) were factored, and the dependent variable (met-
abolic measure) was a continuous variable. Main effects of time and apoE, as well as interaction effect (apoE × 
time) were analysed. Natural variation between participants was considered with an error term. There were no 
significant outliers present in the dataset.
Results
Characteristics of cross-sectional and longitudinal analyses. The summary of the descriptive data 
for the YFS study subjects at the baseline (2001) and the end (2011) of our follow-up is presented in Table 1, the 
frequencies of different apoE genotypes in the study population are shown in Table 2. More details (including 
follow-up data of year 2007) can be found in Supplementary Tables S2 and S3.
Cross-sectional associations of apoE genotypes within 228 tested serum metabolic parame-
ters in YFS. Due to small subgroups of apoE ε2/2 and ε4/2, as well as ε4/4 in our population-based cohort 
(see Table 2), apoE genotypes were clustered into three larger subgroups for better statistical comparison: The 
reference group of ε3/3, as well as ε2+ (consisting of ε2/2 and ε3/2) and ε4+ (including all ε4 carriers: ε4/2, ε4/3 
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and ε4/4). The cross-sectional associations with p < 0.05 after FDR, including 95% CI, of apoE genotypes within 
the total of 228 tested serum metabolic parameters measured during the 10-year follow-up period are illustrated 
in Figs 1–3 and Supplementary Figures S4–6. For a more legible presentation, the statistics with higher p-values 
were excluded from these figures, but are provided in Supplementary datasets S7–9. The data of Figs 1–3 with 
exact p-values is also included in S7–9. Figures 1–3 represent the associations in all subjects, at baseline in 2001 
(154/228 associations with FDR corrected p < 0.05), as well as in 2007 (118/228) and 2011 (180/228) follow-ups 
respectively. In Supplementary Figures 4–6 results obtained from the sex-stratified analyses are shown separately 
for men and women over the same period. Furthermore, the complete results from additional homozygote com-
parisons between ε3/3 and ε4/4 are provided in Supplementary datasets S10–12 – ε2/2 group was too small to be 
analysed separately.
At the end of the follow-up in 2011, by limiting FDR-corrected p < 0.05, multivariate regression analyses 
revealed a total of 180/228 metabolic associations with apoE polymorphisms in all subjects (Fig. 3). ApoE ε4 
allele had a consistent atherogenic and ε2 protective effect across all measured apoE- (chylomicron remnants, 
very-low-density lipoproteins (VLDL), intermediate-density lipoproteins (IDL), high-density lipoproteins 
(HDL)) and apolipoprotein B (apoB) -containing (VLDL, IDL, LDL) lipoproteins with an influence on particle 
concentrations of free/esterified cholesterol, triglycerides, phospholipids and total lipid contents, as well as on 
LDL and VLDL particle sizes. The observed apoE subgroup differences remained relatively consistent during 
the entire 10-year follow-up, although some variation of individual metabolite levels (expressed in SDs from 
the reference group ε3/3) was noticed. There were no apoE × sex interactions found in relation to any studied 
metabolite (p > 0.05), during any of the three different timepoints measured, justifying the main analyses being 
performed with all subjects combined.
In the sex-stratified cross-sectional analyses performed for the three consecutive follow-ups (2001, 2007 and 
2011), it is difficult to distinguish any clearly consistent, sex-specific differences in the associations of individual 
metabolic measures with apoE polymorphism. However, at least as an analytical outcome many of the differences 
between the compared apoE subgroups decrease with men and increase with women towards the 2011 analyses 
(as illustrated in Supplementary Figures S4–6) – especially notable in the apoE ε2+ subgroup. As isolated remarks 
2001 2011
All Male Female All Male Female
Number of subjects 2234 1004 (44.9) 1230 (55.1) 1918 860 (44.8) 1058 (55.2)
Age [years] 31.7 (5.0) 31.7 (5.0) 31.7 (5.0) 41.9 (5.0) 41.9 (5.1) 41.9 (5.0)
BMI [kg/m²] 25.1 (4.4) 25.7 (4.1) 24.5 (4.6) 26.5 (5.0) 27.0 (4.3) 26.1 (5.5)
Daily smokers 533 (23.9) 296 (29.5) 237 (19.3) 263 (13.7) 133 (15.5) 130 (12.3)
Cholesterol lowering medicated 7 (0.3) 6 (0.6) 1 (0.1) 70 (3.6) 48 (5.6) 22 (2.1)
Diabetes mellitus type 2 1 (0.0) 1 (0.1) 0 (0.0) 69 (3.6) 32 (3.7) 37 (3.5)
Hypertension 40 (1.8) 22 (2.2) 18 (1.5) 160 (8.3) 81 (9.4) 79 (7.5)
Total cholesterol [mmol/L] 5.20 (1.12) 5.16 (1.06) 5.24 (1.17) 5.33 (1.07) 5.40 (1.12) 5.27 (1.02)
VLDL cholesterol [mmol/L] 0.81 (0.31) 0.90 (0.32) 0.75 (0.29) 0.76 (0.33) 0.88 (0.35) 0.67 (0.27)
IDL cholesterol [mmol/L] 0.83 (0.23) 0.84 (0.22) 0.82 (0.23) 0.86 (0.22) 0.88 (0.23) 0.83 (0.20)
LDL cholesterol [mmol/L] 1.94 (0.60) 2.00 (0.61) 1.89 (0.60) 2.05 (0.60) 2.17 (0.63) 1.96 (0.57)
HDL cholesterol [mmol/L] 1.78 (0.42) 1.43 (0.33) 1.78 (0.42) 1.65 (0.42) 1.46 (0.36) 1.81 (0.40)
Triglycerides [mmol/L] 1.29 (0.69) 1.45 (0.73) 1.17 (0.62) 1.31 (0.87) 1.57 (0.96) 1.10 (0.73)
apoA-I [g/L] 1.68 (0.27) 1.59 (0.21) 1.76 (0.28) 1.70 (0.24) 1.62 (0.21) 1.77 (0.25)
apoB [g/L] 0.98 (0.24) 1.03 (0.24) 0.94 (0.23) 1.00 (0.25) 1.08 (0.26) 0.93 (0.22)
Table 1. Summary descriptive data for the YFS cohort in 2001 and 2011. Values are mean (SD) or n (%). 
Abbreviations: BMI, body mass index; VLDL, very-low-density lipoprotein; IDL, intermediate-density 
lipoprotein; LDL, low-density lipoprotein; HDL, high-density lipoprotein; apoA-I, Apolipoprotein A-I; apoB, 
Apolipoprotein B.
2001 2011
All Male Female All Male Female
ε2/2 4 (0.2) 2 (0.2) 2 (0.2) 4 (0.2) 2 (0.2) 2 (0.2)
ε3/2 142 (6.4) 46 (4.6) 96 (7.8) 130 (6.8) 47 (5.5) 83 (7.8)
ε3/3 1280 (57.3) 585 (58.3) 695 (56.5) 1096 (57.1) 495 (57.6) 601 (56.8)
ε4/2 44 (2.0) 18 (1.8) 26 (2.1) 36 (1.9) 13 (1.5) 23 (2.2)
ε4/3 684 (30.6) 317 (31.6) 367 (29.8) 578 (30.1) 271 (31.5) 307 (29.0)
ε4/4 80 (3.6) 36 (3.6) 44 (3.6) 74 (3.9) 32 (3.7) 42 (4.0)
TOTAL 2234 1004 1230 1918 860 1058
Table 2. Frequencies, n (%), of different apoE genotypes in the YFS cohort in 2001 and 2011.
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Figure 1. ApoE effects on 154/228 (p < 0.05 after false discovery rate correction) NMR-based serum metabolic 
measures in all subjects (n = 2234) of YFS cohort participated in 2001. Statistics: Regression models are adjusted 
for age, BMI and sex. Regression β-coefficients (x-axis) indicate in standard deviation (SD) units the change in 
metabolite level over apoE genotype subgroups (ε2+, ε3/3, ε4+). The most common ε3/3 subgroup (n = 1280) 
is set at the origin (zero SD) and post-hoc compared with ε2+ (squares) and ε4+ subgroups (circles). β-values 
with 95% CI are scaled to SD increments from normalized i.e., ln-transformed metabolic measures. For clarity 
of illustration, only the results of the analyses with p < 0.05 after false discovery rate correction are shown 
here. Definitions: apoE ε2+ subgroup (ε2/2, ε3/2 combined; n = 146) and apoE ε4+ subgroup (ε4/2, ε4/3, ε4/4 
combined; n = 808).
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on sex-stratified results, elevation of glycoprotein acetyls (GlycA) and isoleucine levels (with p < 0.05 after FDR) 
were found only in the apoE ε4+ group of men, in the 2011 follow-up (see Supplementary Figure S6).
Possible effects of interactions between the main term (apoE genotype) and the covariates (described in 
Materials and methods Section) in the multivariate linear regression model were all tested to have either zero or 
negligible weight on the cross-sectional association outcomes (apoE β-values). Therefore, interaction terms were 
excluded from the final models.
Our metabolomics lipid results were parallel/confirmed using standard lipid panels. Total cholesterol, LDL-C, 
as well as apoB were all elevated among the apoE ε4 allele carriers and lowered among the ε2 carriers as compared 
with the most common apoE ε3/3 group, in all follow-up points, as expected (data not shown here). In addition, 
at the end of our follow-up period in 2011 ε4 carriers expressed also elevated TG and lowered HDL-C – these two 
parameters did not differ statistically between the ε2 carriers and the ε3/3 group at any follow-up measurement.
Figure 2. ApoE effects on 118/228 (p < 0.05 after false discovery rate correction) NMR-based serum metabolic 
measures in all subjects (n = 2148) of YFS cohort participated in 2007. Statistics: Regression models are adjusted 
for age, BMI and sex. Regression β-coefficients (x-axis) indicate in standard deviation (SD) units the change in 
metabolite level over apoE genotype subgroups (ε2+, ε3/3, ε4+). The most common ε3/3 subgroup (n = 1235) 
is set at the origin (zero SD) and post-hoc compared with ε2+ (squares) and ε4+ subgroups (circles). β-values 
with 95% CI are scaled to SD increments from normalized i.e., ln-transformed metabolic measures. For clarity 
of illustration, only the results of the analyses with p < 0.05 after false discovery rate correction are shown 
here. Definitions: apoE ε2+ subgroup (ε2/2, ε3/2 combined; n = 144) and apoE ε4+ subgroup (ε4/2, ε4/3, ε4/4 
combined; n = 769).
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Figure 3. ApoE effects on 180/228 (p < 0.05 after false discovery rate correction) NMR-based serum metabolic 
measures in all subjects (n = 1918) of YFS cohort participated in 2011. Statistics: Regression models are adjusted 
for age, BMI and sex. Regression β-coefficients (x-axis) indicate in standard deviation (SD) units the change in 
metabolite level over apoE genotype subgroups (ε2+, ε3/3, ε4+). The most common ε3/3 subgroup (n = 1096) 
is set at the origin (zero SD) and post-hoc compared with ε2+ (squares) and ε4+ subgroups (circles). β-values 
with 95% CI are scaled to SD increments from normalized i.e., ln-transformed metabolic measures. For clarity 
of illustration, only the results of the analyses with p < 0.05 after false discovery rate correction are shown 
here. Definitions: apoE ε2+ subgroup (ε2/2, ε3/2 combined; n = 134) and apoE ε4+ subgroup (ε4/2, ε4/3, ε4/4 
combined; n = 688).
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Figure 4. ApoE effects on the longitudinal changes (i.e., calculated difference between 2007–2011) of 
44/228 (p < 0.05 after false discovery rate correction) NMR-based serum metabolic measures in all subjects 
participated in both follow-ups (n = 1734). Statistics: Regression models are adjusted for age, sex, baseline BMI 
and BMI-change. Regression β-coefficients (x-axis) indicate in standard deviation (SD) units the difference of 
metabolite level change between two apoE genotype subgroups (ε4− and ε4+). ε4− group is set at the origin 
(zero SD) and post-hoc compared with ε4+ group (circles). β-values with 95% CI are scaled to SD increments 
from normalized i.e., ln-transformed metabolic change measures. For clarity of illustration, only the results of 
the analyses with p < 0.05 after false discovery rate correction are shown here. Definitions: apoE ε4− subgroup 
(ε2/2, ε3/2, ε3/3 combined; n = 1112) and apoE ε4+ subgroup (ε4/2, ε4/3, ε4/4 combined; n = 622).
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Longitudinal differences between apoE genotypes within 228 tested serum metabolic param-
eters in YFS. Longitudinal changes within 228 serum metabolic parameters and possible variation over 
apoE genotypes were investigated using calculated level differences between two follow-up measurements (i.e., 
2001–2011, 2001–2007 and 2007–2011). For improved statistical power, apoE genotypes were clustered into 
two subgroups: The reference group of apoE ε4− (consisting of ε2/2, ε3/2 and ε3/3) and apoE ε4+ (including 
ε4/2, ε4/3 and ε4/4). For distinguishing any differences between the two compared subgroups, we discovered 
that it was essential to adjust the multivariate linear regression models also with the change of body mass index 
(BMI). Finally, 44/228 differences limited by p < 0.05 after FDR were found, however, only in the analyses of the 
follow-up interval of 2007–2011. These results are illustrated in Fig. 4. Allowing a more legible presentation, the 
Figure 5. Repeated measures of six selected NMR-quantified and previously identified novel serum risk 
biomarkers in different apoE groups of all subjects (n = 1471) participated every three follow-ups (2001, 2007 
and 2011) within YFS cohort. Statistics: According to two-way repeated measures analyses of variances, every 
presented metabolic measure expresses a main effect of apoE with p < 0.05 without any main effect of time or 
interaction effect (p ≫ 0.05). ApoE subgroup means are shown in absolute scale with 95% CI. Definitions: apoE 
ε2+ subgroup (ε2/2, ε3/2 combined; n = 98; squares), apoE ε3/3 subgroup (n = 846; triangles) and apoE ε4+ 
subgroup (ε4/2, ε4/3, ε4/4 combined; n = 527; circles).
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statistics with higher p-values were excluded from this figure, but are provided in Supplementary Dataset S13. 
The data of Fig. 4 with exact p-values is also included in S13. Consistently increased differences of VLDL- and 
TG-related metabolites can be observed among the apoE ε4+ subgroup. The effects of main term (apoE geno-
type) and covariate (described in Materials and methods Section) interactions were tested to be of no relevance, 
and therefore the interaction terms were excluded from the final models.
Novel associations of apoE polymorphism with previously identified biomarkers of CAD, 
inflammation, diabetes and all-cause mortality. In the cross-sectional analyses of all subjects, as novel 
findings apoE ε4 associated with altered levels of previously identified risk biomarkers, the repeated measures 
averages of which (with 95% CI) are also illustrated in Fig. 5. One missing GlycA measure in 2001 and 2007, 
as well as four isoleucine measures in 2001 and one in 2007 were mean value replaced. The concentrations of 
inflammation and all-cause mortality reflecting GlycA, as well as diabetogenic branched chain amino acid iso-
leucine were elevated in apoE ε4+ group. Furthermore, smaller LDL particle diameter as well as increased con-
centrations of LDL-TG, VLDL-TG and (medium-size, M)VLDL have been linked to elevated risk of CAD – all 
associated also with apoE ε4+ in our present analyses. According to verifying repeated measures analyses of 
variances, main effect of apoE with p < 0.05 was found for every parameter presented in Fig. 5. However, there 
were no main effects of time or interaction effects (apoE × time) present (p ≫ 0.05). All exact p-values are listed 
in Supplementary Dataset S14.
Discussion
In the present study, apoE polymorphism associated consistently and as expected over the followed years with 
plasma concentrations of basic lipids i.e., total cholesterol, LDL-C and apoB (as widely reported in literature, 
including the previous YFS follow-up23). However, as new information apoE ε4 allele also presented a consistent 
atherogenic effect across all measured apoE- (chylomicron remnants, VLDL, IDL, HDL) and apoB-containing 
(VLDL-, IDL-, LDL) lipoproteins along with their subfractions, showing an influence on particle concentrations 
of free/esterified cholesterol, triglycerides, phospholipids and total lipid contents, as well as on LDL and VLDL 
particle sizes in serum. In addition, ε2 allele demonstrated an opposite, protective impact. Furthermore, to our 
knowledge as previously unreported findings, apoE ε4 also associated with altered levels of certain previously 
identified novel risk biomarkers of CAD, inflammation, diabetes and all-cause mortality.
Our cross-sectional results of apoE genotype effects on serum lipid and lipoprotein metabolites in all subjects 
are consistently in line with the metabolic mechanisms reviewed in detail in6,32,33. Briefly summarized, apoE pol-
ymorphism alters the hepatic binding, uptake, and catabolism of apoE- and apoB-containing lipoproteins, as well 
as intestinal cholesterol absorption, bile acid formation and endogenous cholesterol synthesis. In addition, after 
fat ingestion the shifting of apoE proteins between lipoproteins, as well as lipoprotein conversion and production 
rates are all suggested to depend on the apoE phenotypes. In ε4 carriers these mechanisms can lead to hyper-
cholesterolemia and pro-atherogenic circulating lipoprotein-cholesterol distributions such as more cholesterol 
enriched chylomicron remnants and apoB-containing lipoproteins, as well as higher VLDL-C/HDL-C ratio5,6,32. 
More recently, ε4 has also been reported to unfavourably change the lipid composition and distribution in cell 
plasma membranes, as well as to associate with increased cytoplasmic lipids34. Elevated membranous and cyto-
plasmic cholesterol levels have been demonstrated with ε4, and increased membranous phospholipids, as well 
as cytoplasmic cholesteryl esters and TGs have been found in apoE deficiencies – all possibly promoting various 
heart anomalies34. The role of ε2 allele has been debated on one hand to be protective against dyslipidaemias and 
CAD, but on the other hand to promote type III hyperlipoproteinemia. However, the adverse effect of ε2 has been 
reported to manifest only in case of rare homozygosity (ε2/2) combined with additional genetic or environmental 
stress, e.g., obesity and high-fat diet6. On the other hand, references indicate possible race-dependence, e.g., ε2 
being protective among Caucasians, but a potential risk factor in Asians17. In our Caucasian study population with 
only a few ε2/2 homozygotes ε2 has clearly a protective role – although, the relative quantities of TGs are elevated 
among the ε2+ subgroup (see ‘Lipid ratios’ in Figs 1–3). In addition, ε2 would seem to have even a bigger impact 
on our study population than ε4, which is well in line with the reference findings of ε2 cholesterol-lowering effect 
being 2–3 times that of the ε4 cholesterol-raising effect5.
In our longitudinal association analyses comparing metabolite level differences, a consistent increase of 
VLDL-related serum metabolites and TGs was found in the ε4+ subgroup (see Fig. 4). Results limited with 
FDR-corrected p < 0.05 were found only in the follow-up interval of 2007–2011 – however, as illustrated in Fig. 5 
with VLDL-TG and MVLDL particle concentrations, this might be reasoned by variable metabolite trending 
along our follow-up period, experienced also in other reference studies such as in35 with serum cholesterols. 
Moreover, longitudinal associations were found only after adding the change of BMI into the multivariate lin-
ear regression model as a covariate – distinguishing the parallel effect of ε4 allele from the overall weight-gain 
throughout our entire study population (increase of mean BMI also notable in Table 1 and Supplementary 
Table S2). The number of reference studies reporting longitudinal follow-up findings is very limited. However, 
our results are well in line with an early study of standard serum lipid profile changes, where increased TG levels 
were found in the ε4+ subgroup in conjunction with a weight gain36. TG elevation was suggested to be caused 
by an increased VLDL production due to weight-gain, accompanied by retarded VLDL clearance attributable to 
the ε4 allele – the mechanism of which is explained deeper in a review by Phillips6. Indeed, our longitudinal, as 
well as cross-sectional results could well support this theory. Epidemiology and genetics have indicated that ele-
vated TG-rich lipoproteins represent risk factors for low-grade inflammation, atherosclerotic CVD, and all-cause 
mortality37.
Low total HDL-C level, which has been epidemiologically linked to an increased risk of atherogenesis as a 
biomarker38, was at least partially evident in our ε4 carriers – observed at the end of our follow-up (2011) in all 
subjects. More consistently, ε4 allele associated with low cholesterol of large- and medium-sized HDL-particles. 
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However, also ε2 carriers indicated lower cholesterol levels of extremely large and small HDL-particles, as well as 
of HDL3 subfractions. Based on present knowledge, it may be difficult to interpret whether the cholesterol con-
tents of different HDL subpopulations could have any predictive value. Recent human genetics findings indicate 
that HDL-C concentration is unlikely a causative factor of atherosclerotic CVD39,40. In addition, a comprehensive 
literature review of HDL2 and HDL3 cholesterol does not distinguish cardioprotective differences between HDL 
subclasses, despite prior opposite hypothesis41. Furthermore, ongoing discussion and research have pointed out 
the extremely heterogenous composition of HDL particles with diverse functionalities, undergoing constantly 
dynamic changes of protein and lipid contents38,42,43. Hence, HDL-C may be a snapshot of a highly dynamic 
process, not describing as such the HDL particle structure or functionality. Nevertheless, certain variation of the 
HDL cholesterol profiles persisted between our apoE subgroups, assessed by multiple measurements.
Increasing evidence points towards evoked inflammatory mechanisms behind the early development of ath-
erosclerotic plaque formation44. In terms of apoE ε4-promoted early inflammation, a previous YFS follow-up 
study discovered lower hs-CRP levels in certain subgroups of ε4 carriers – not giving evidence as such for this 
hypothesis45. On the other hand, glycoprotein acetyls (GlycA) is a novel biomarker of systemic inflammation, and 
elevated baseline circulating GlycA has been found to associate also with a future risk of CAD14,46,47. In our pres-
ent cross-sectional analyses in the same YFS cohort, elevated GlycA level was found in the apoE ε4+ subgroup: 
In all subjects in the 2001 and 2011 follow-ups (Figs 1, 3 and 5), as well as in men separately in the 2011 follow-up 
(see Supplementary Figure S6). This new finding could support the role of apoE ε4 in possible early inflammatory 
provoked processes – either as a promoter, or a biomarker. In addition to inflammation, GlycA has also been 
reported to strongly predict the short-term risk of all-cause mortality28,48.
Small LDL particle diameter has been independently linked to atherogenesis and elevated risk of CVD, as well 
as all-cause mortality – potentially due to decreased LDL receptor binding and longer residence time in plasma, 
increased permeability through the endothelial barrier, arterial proteoglycan binding and susceptibility to oxida-
tion (e.g.49,50). In our results, the difference in LDL diameter between the apoE subgroups persisted throughout 
the entire follow-up interval – ε4 allele associating with decreased, ε2 with increased mean diameter compared 
with ε3/3.
Increased levels of certain branched chain amino acids in the blood have been reported to flag up potentially 
developing diabetes mellitus type 2 later in life – possibly due to uncoupling of insulin receptors by persistent 
activation of mTOR pathway, or mitochondrial dysfunction by accumulation of toxic amino acid metabolites51. 
A recent review associate isoleucine (and leucine, not valine) with insulin resistance and higher blood glucose 
levels51. Isoleucine has been previously associated with insulin resistance also in the YFS cohort follow-up of 
2001–200752 – although this effect was only seen in men. In our current analyses, isoleucine was elevated by the ε4 
allele in all subjects in 2001 and 2011 (see Figs 1 and 3 respectively), as well as in men in 2011 (see Supplementary 
Fig. S6).
As mentioned in the Introduction, LDL-C as such may not have the sensitivity or specificity needed to dis-
tinguish CAD risk within all the subjects with elevated LDL-C14. On the other hand, many CAD patients may 
have fairly normal LDL-C15. One of the suggested markers for predicting better the atherogenic potential of 
LDL is LDL-TG – high LDL-TGs being reported to indicate cholesterol ester-depleted LDL, elevated IDL and 
dense LDL15. In our analyses, lowered LDL-TG levels by the ε2 allele and elevated by the ε4 allele can be noted 
throughout the entire follow-up period. On the other hand, there is also discussion on turning focus from mere 
LDL also to IDL and VLDL – receiving support from the reviewed novel biomarkers for CAD, as well14. Higher 
concentrations of IDL, MVLDL and SVLDL have been associated with CAD risk, also in a Finnish population53 – 
all of which are elevated by the ε4 allele in our analyses. And as discussed earlier, our longitudinal analyses would 
indicate even a growing tendency of VLDL and TG over time in the ε4 carriers (see Fig. 4).
Our study has several important strengths. There are no prior systematic studies on the effect of apoE poly-
morphism on serum metabolome, most studies having limited to standard lipid panels. Moreover, earlier apoE 
studies have not implemented the NMR-method, which allows more detailed analyses and better resolution to 
compare different subgroups – especially important in distinguishing variations already prior to diagnosed dis-
orders. In addition, our longitudinal follow-up with a continuously high participation rate revealed statistically 
consistent patterns evident within clusters of interlinked metabolic measures, significantly limiting the likeli-
hood of mere isolated random positive hits. Also, the comprehensive background information gathered from our 
cohort allowed a thorough analysis and consideration of the most expected confounding factors. Furthermore, 
our analyses reflect genotype-related differences in a basically healthy general population – avoiding confound-
ing/confusing expressions of illnesses expected when using morbid study subjects.
We also acknowledge certain limitations in our study. As previously reported in Finnish general population7,13, 
subgroups of apoE ε2/2, ε4/2, as well as ε4/4 were small also in our population-based setting and did not allow 
complete analyses of all the six genotypes separately. And although our cohort was not small by any means, its 
size may still have limited a completely comprehensive comparison between (sex-stratified) men and women, as 
more statistical power may be needed to distinguish all the small, emerging metabolic differences – nevertheless, 
the absence of apoE x sex interactions was confirmed in the analyses of all subjects. Finally, dietary fat intake, the 
rate of which was uncontrolled during our standard follow-up, has been reported to influence the magnitude of 
the observed exposure to apoE genotypes54, e.g., by altering the LDL-receptor binding of the E4 isoform55 – thus, 
generally lower levels of SFA intake within study subjects may possibly lead to smaller apoE genotype-related 
differences in serum metabolic measures. Nevertheless, based on reference studies (e.g.5,7,54) these recognized 
limitations do not alter the effect directions related to different apoE alleles, and are thus less likely to have a major 
impact on our main discoveries presented and discussed here.
In conclusion, based on a thorough NMR quantification of serum metabolome apoE polymorphism is asso-
ciated with a complex metabolic change, including aberrations in multiple new biomarkers related to elevated 
cardiometabolic and all-cause mortality risk, extending our understanding about the role of apoE in health and 
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disease. These changes are already evident in a basically healthy general population. For further work, the asso-
ciations of more specifically quantified serum lipidomics data should also be analysed over the apoE genotypes, 
as certain TGs, cholesterol esters, PGs (phosphatidylethanolamines) and sphingomyelins (ceramides) have pre-
sented the strongest found novel associations with increased risk of CAD14,56 – in our study, elevated associations 
of all these lipid groups can be detected also in the apoE ε4+ subgroup (lowered in the ε2+ subgroup), and it 
is well expected to reveal more common nominators in the reported pool of novel risk markers. The relation-
ship between the current new metabolic findings and pathogenesis, as well as different clinical manifestations 
should also be investigated using e.g., metabolic pathway analysis approach. For future analysis and upcoming 
end-points, the follow-up of the YFS cohort is also continuing.
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